Clarification

A story about Oxigene Inc. in the Sept. 23 issue of BioWorld Today should have said the company's first-generation radiation sensitizer, Sensamide, was the subject of a Phase II/III study. The results of that study altered a Phase III study of the company's second generation compound, Neu-Sensamide.